Diagnostic Center | June 26, 2024
Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Subscribe To Our Newsletter & Stay Updated
